TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05156190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bright classrooms with light level over 1000 lux
Description: Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
Study: NCT05845138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 for injection ; capecitabine
Description: SHR-A1811 for injection; Capecitabine tablets
Study: NCT05684081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital payment
Description: The proposed intervention is designed to support the implementation of polio campaigns through digital payments
Study: NCT06336668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk-based HMF
Description: The study subject will be fed human milk fortified with a human-milk-based HMF.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk-based HMF
Description: The study subject will be fed human milk fortified with a human-milk-based HMF.
Study: NCT05485805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and caffeine (BAY2880376)
Description: Tablet, oral use, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and caffeine (BAY2880376)
Description: Tablet, oral use, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (Aleve)
Description: Tablet, oral use, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Tablet, oral use, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral use, single dose
Study: NCT04820855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cares
Description: This is standard treatment for Interstitial cystitis with your provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Cares
Description: This is standard treatment for Interstitial cystitis with your provider.
Study: NCT06241248

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid sepsis diagnostic test
Description: The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
Study: NCT05824182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FACE self-help App
Description: The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
Study: NCT06053476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Description: After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot paravertebral block
Description: At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot paravertebral block
Description: At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
Study: NCT05736016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)
Description: All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)
Description: All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
Study: NCT04675086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1-proteinase inhibitor
Description: Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
Study: NCT06503796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4mg/kg/d, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
Study: NCT06437132

Intervention type: OTHER
Intervention: No intervention
Description: The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
Study: NCT05296512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib.
Study: NCT05769075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-2136b
Description: Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-2136b
Description: Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage
Study: NCT06053476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system
Study: NCT04675086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiviral Agents
Description: a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Agents
Description: a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
Study: NCT06053476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system
Study: NCT05227001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07852352 Influenza saRNA 1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07852352 Influenza saRNA 1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07852352 Influenza saRNA 1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836391 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836391 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836391 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836394 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836394 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836394 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836395 Influenza saRNA
Description: Intramuscular injection
Study: NCT05986838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aser puncture
Description: laser puncture (3 sessions per week)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultraviolet radiatio
Description: ultraviolet radiation (3 sessions per week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: for 3 months
Study: NCT05227001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836395 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836395 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836396 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836396 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836396 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07867246 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07867246 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07867246 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine (QIV)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07871987 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07871987 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07871987 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07914705 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07914705 Influenza saRNA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07915048 Influenza saRNA
Description: Intramuscular injection
Study: NCT04760093

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
Study: NCT06304831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality ratings of health care providers for children
Description: Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
Study: NCT06270966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Remediation
Description: Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions.
Study: NCT04781374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
Study: NCT05489185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous or topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous or topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous or topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous or topical administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: Placebo
Study: NCT06543602

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-model monitoring and alert
Description: All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
Study: NCT05725590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent
Description: All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal pancreatic duct stent
Description: All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
Study: NCT05089994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided injection
Description: using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided injection
Description: using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.